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Background
Major depressive disorder (MDD) is a common and dis-
abling psychiatric condition. Antidepressants are cur-
rently the mainstay of treatment for depression;
however, almost two thirds of patients will fail to
achieve remission with initial treatment, as a result, a
range of augmentation and combination strategies have
been used [1].
Materials and methods
Major depressive disorder (MDD) is a common and dis-
abling psychiatric condition. Antidepressants are cur-
rently the mainstay of treatment for depression;
however, almost two thirds of patients will fail to
achieve remission with initial treatment, as a result, a
range of augmentation and combination strategies have
been used [1].
Results
Mood stabilizers are used in 14% of the sample with a
predominancy in the female gender (85.7%), a global
average age 50.6 ± 12.2 years. Regarding personal psy-
chiatric background, there’s an absence of these in the
first place (64.3%), followed by the presence of previous
depressive episodes (21.4%) and dysthymic disorder
(7.1%). In none of these cases there was toxic abuse.
There is a predominancy in the absence of previous
psychiatric hospitalisations (64.3%).
The frequencies of use of mood stabilizers was: topira-
mate in the first place (50%) followed by lithium, carba-
mazepine and pregabaline (14.28% each of them), in the
last place lamotrigine (7.1%). The average dose was
900 mg/d for carbamazepine, 600 mg/d for lithium,
300 mg/d for pregabaline, 128.5 mg/d for topiramate
and 100 mg/d for lamotrigine.
Conclusions
In our sample the frequency of use of lithium is similar
to the registered for the several antiepiletics (lithium,
carbamazepine and pregabaline: 14.28% each one). How-
ever, lithium addition is recommended as a first choice
for depressed patients who do not respond to therapy
with conventional antidepressants [2].
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